Netherlands-based Nucletron today announced the introduction of its treatment planning system, the Oncentra Brachy, which is now pending U.S. FDA approval.
The volume-based treatment planning system is designed to optimize cancer treatment planning with brachytherapy. According to the company, it is the world’s first fully DICOM-compatible treatment planning system, featuring state-of-the-art optimization algorithms to ensure efficient treatment.
It offers 3D contouring and margining tools to identify regions of interests (ROIs) on CT or in multimodality imaging environments using image registration for CT, MR and PET data. It also has capabilities for real-time information sharing, allowing for remote access and authorization of treatment plans.